Researchers at Duke University Medical Center and Vanderbilt University Medical Center have pinpointed the first major gene that determines an individuals risk for developing age-related macular degeneration (AMD). The chronic, progressive disease -- which affects as many as 15 million people in the United States -- is the leading cause of visual impairment and legal blindness in the elderly.
A common variant of the gene, called complement factor H (CFH), explains approximately 43 percent of the risk of AMD among older adults, the researchers estimated. The team identified the disease-related gene after screening 182 families affected by AMD and 495 other individuals with the condition. The researchers will report their findings in a forthcoming issue of Science (published online March 10, 2005, in Science Express).
The genetic advance sheds light on the mechanisms underlying the disease and could lead to new avenues for treatment, the researchers said. The finding might also yield methods for identifying those patients at the greatest risk for developing the condition before symptoms arise, when therapies and changes in lifestyle might be most effective in slowing the disease progression. "Macular degeneration is an important cause of blindness and loss of independence in the elderly," said Margaret Pericak-Vance, Ph.D., director of the Duke Center for Human Genetics and senior author of the report. "This gene opens the door to a whole new understanding of the factors that contribute to this disease. "The finding may ultimately lead to new methods for identifying those at high risk for macular degeneration and suggests new pathways for drug development," she added.
Kendall Morgan | EurekAlert!
Ion treatments for cardiac arrhythmia — Non-invasive alternative to catheter-based surgery
20.01.2017 | GSI Helmholtzzentrum für Schwerionenforschung GmbH
Seeking structure with metagenome sequences
20.01.2017 | DOE/Joint Genome Institute
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
20.01.2017 | Awards Funding
20.01.2017 | Materials Sciences
20.01.2017 | Life Sciences